Results 1 to 10 of about 11,874 (152)

Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis. [PDF]

Ther Adv Neurol Disord
Ebne-Ali-Heydari Y, Ramezani A, Jozayi A, Norouzi M, Zohrabi P, Kaveyee H.   +5 more
europepmc   +1 more source

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. [PDF]

Eur J Neurol
Maersk-Moller C, Pontieri L, Stilund MLM, Christensen JR, Storr LK, Hansen V, Schäfer J, Weglewski A, Romani KQ, Jensen HB, Illes Z, Papp V, Sejbaek T, Poulsen MB, Kant M, Torring CW, Sellebjerg F, Magyari M, DMSG Group.   +18 more
europepmc   +1 more source

Progressive multifocal leukoencephalopathy - a diagnostic guide for the clinical neurologist. [PDF]

Front Neurol
Jia DT.
europepmc   +1 more source

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study. [PDF]

Neurotherapeutics
Brummer T, Räuber S, Jakob J, Willison AG, Schraad M, Protopapa M, Fleischer MI, Boeckers JM, Ruck T, Meuth SG, Zipp F, Fleischer V, Bittner S.   +12 more
europepmc   +1 more source

Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives. [PDF]

Neurol Ther
Preziosa P, Guido G, Filippi M, Rocca MA.   +3 more
europepmc   +1 more source

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center. [PDF]

Arq Neuropsiquiatr
Simon-Nogueira AB, Holanda AC, Rosalem RA, Santillan TIV, Silva GD, Apostolos-Pereira SL, Adoni T, Callegaro D, Spricigo MG, Oliveira MB.   +9 more
europepmc   +1 more source

Managing reactivation of multiple sclerosis during treatment with natalizumab. [PDF]

Mult Scler
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, Butzkueven H, Lechner-Scott J, Buzzard K, Skibina O, Gerlach O, Prat A, Girard M, Duquette P, Alroughani R, Patti F, Grand'Maison F, Sá MJ, Aguera-Morales E, Hodgkinson S, Grammond P, Kuhle J, Yamout B, Khoury SJ, Ozakbas S, Csepany T, John N, Laureys G, Terzi M, Amato MP, Boz C, Al-Asmi A, Cartechini E, Gouider R, Mrabet S, Roos I, Kalincik T.   +36 more
europepmc   +1 more source

CD56^brightNK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy. [PDF]

Clin Transl Immunology
Perkins GB, Hope CM, Chai CS, Tunbridge MJ, Sterling S, Webb K, Yap J, Yeow AEL, Masavuli MG, Scaffidi J, Zuiani JD, Akerman A, Aggarwal A, Milogiannakis V, Roberts MB, Hurtado PR, Turville S, Grubor-Bauk B, Barry SC, Ravindran J, Coates PT, Hissaria P.   +21 more
europepmc   +1 more source

Clinical relevance and predictors of anti-natalizumab antibodies in multiple sclerosis: A real-world retrospective cohort study. [PDF]

Mult Scler J Exp Transl Clin
Levy M, Beigneux Y, Roux T, Mossad M, Ricigliano V, Senant M, Papeix C, Stankoff B, Louapre C, Maillart E, Lazzarotto A.   +10 more
europepmc   +1 more source

Refined single-cell profiling captures a CCR5^high CD4⁺ cytotoxic T-cell precursor in multiple sclerosis. [PDF]

EBioMedicine
van Puijfelik F, Rip J, van Hasselt Y, Wierenga-Wolf AF, Shyfrin S, Pelser AC, Melief MJ, Klein Kranenbarg RAM, Bindels EM, van de Werken HJG, van Ansenwoude CMJ, de Vries HE, Dik WA, de Beukelaar J, Smets I, Wokke BH, Smolders J, van Luijn MM.   +17 more
europepmc   +1 more source